Screener
Whitehawk Therapeutics WHWK Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -68.5%-86.2pp | -21.8%+59.0pp | -13.8%+52.1pp | -8.3%+54.0pp | 17.7%+75.9pp | |
| Efficiency | ||||||
| Asset turnover | 0×-0.2× | 0.1×-0.2× | 0.1×— | 0.2×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 11.4×-7.6× | 10.3×+6.7× | 16.8×+11.9× | 20.4×+16.2× | 19×+13.8× | |
| Per Share | ||||||
| Book value per share | $1.68-69.8% | $2.20+13.4% | $2.27-10.8% | $2.49-14.6% | $5.55+65.6% | |
| Valuation | ||||||
| Market capitalization | $197.82M+93.4% | $114.05M— | $89.54M— | $89.04M— | —— | |
| Price / book | 1.7×+1.1× | 0.8×— | 0.6×— | 0.5×— | —— |
FAQ
- What are Whitehawk Therapeutics's profit margins?
- Whitehawk Therapeutics (WHWK) runs a 89.4% gross margin and a -1601.1% operating margin, with a -288.3% net margin.
- Where do Whitehawk Therapeutics's ratios come from?
- Every ratio is computed from Whitehawk Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.